Raiffeisen Switzerland B.V. Stock

Certificat

LVQRCH

CH1251124470

Market Closed - Swiss Exchange 11:20:00 2024-02-27 am EST
57.03 CHF +0.28% Intraday chart for Raiffeisen Switzerland B.V.
1 month-18.11%
3 months-17.07%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Raiffeisen Switzerland B.V.
LVQRCH
ISINCH1251124470
Date issued 2023-03-31
Strike 261 CHF
Maturity 2025-01-06 (218 Days)
Parity 0.26 : 1
Emission price 100 CHF
Emission volume N/A
Settlement both
Currency CHF

Technical Indicators

Highest since issue 102.4 CHF
Lowest since issue 55.08 CHF

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231 CHF
Average target price
277.5 CHF
Spread / Average Target
+20.14%
Consensus
  1. Stock Market
  2. Certificates
  3. LVQRCH Certificat